| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Breaks, Double-Stranded | 6 | 2020 | 68 | 1.290 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 45 | 0.890 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2021 | 7 | 0.720 |
Why?
|
| Submandibular Gland | 1 | 2021 | 18 | 0.720 |
Why?
|
| Parotid Neoplasms | 1 | 2021 | 16 | 0.720 |
Why?
|
| Parotid Gland | 1 | 2021 | 26 | 0.720 |
Why?
|
| Primed In Situ Labeling | 1 | 2020 | 1 | 0.720 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 27 | 0.710 |
Why?
|
| Cyclin E | 7 | 2016 | 28 | 0.710 |
Why?
|
| DNA Repair | 3 | 2020 | 366 | 0.700 |
Why?
|
| Dermatofibrosarcoma | 1 | 2019 | 14 | 0.630 |
Why?
|
| Vena Cava, Superior | 1 | 2019 | 60 | 0.610 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 66 | 0.610 |
Why?
|
| Ventricular Remodeling | 3 | 2015 | 109 | 0.580 |
Why?
|
| Cardiomegaly | 2 | 2015 | 121 | 0.540 |
Why?
|
| Histones | 2 | 2018 | 351 | 0.540 |
Why?
|
| Mutation | 11 | 2024 | 4204 | 0.530 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 2394 | 0.510 |
Why?
|
| Data Mining | 1 | 2016 | 44 | 0.490 |
Why?
|
| Genomic Instability | 4 | 2020 | 84 | 0.490 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2016 | 169 | 0.490 |
Why?
|
| Chromatin | 1 | 2018 | 417 | 0.480 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2015 | 4 | 0.480 |
Why?
|
| Smad3 Protein | 1 | 2015 | 25 | 0.480 |
Why?
|
| DNA | 1 | 2020 | 1308 | 0.470 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2024 | 105 | 0.470 |
Why?
|
| Myocardium | 2 | 2015 | 586 | 0.470 |
Why?
|
| Aortic Aneurysm | 1 | 2015 | 79 | 0.460 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2020 | 46 | 0.450 |
Why?
|
| Extracellular Matrix | 3 | 2019 | 250 | 0.440 |
Why?
|
| Fibrosis | 2 | 2015 | 239 | 0.440 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 606 | 0.430 |
Why?
|
| Aorta | 1 | 2015 | 291 | 0.430 |
Why?
|
| Intellectual Disability | 3 | 2020 | 190 | 0.420 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 328 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 622 | 0.400 |
Why?
|
| DNA Replication | 4 | 2020 | 173 | 0.400 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 335 | 0.380 |
Why?
|
| Humans | 52 | 2024 | 92337 | 0.330 |
Why?
|
| Breast Neoplasms | 8 | 2020 | 3053 | 0.330 |
Why?
|
| Female | 37 | 2024 | 47893 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 1138 | 0.320 |
Why?
|
| Nephrotic Syndrome | 3 | 2005 | 33 | 0.300 |
Why?
|
| Whole Genome Sequencing | 2 | 2019 | 103 | 0.300 |
Why?
|
| Obesity | 1 | 2015 | 1016 | 0.290 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1576 | 0.290 |
Why?
|
| Muscle Hypotonia | 2 | 2018 | 49 | 0.290 |
Why?
|
| Male | 31 | 2024 | 43925 | 0.280 |
Why?
|
| Immunohistochemistry | 4 | 2024 | 1807 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase 2 | 3 | 2016 | 25 | 0.260 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2006 | 22 | 0.250 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 89 | 0.240 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 2669 | 0.240 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 66 | 0.230 |
Why?
|
| Blood Platelets | 1 | 2004 | 148 | 0.220 |
Why?
|
| Thyroid Nodule | 1 | 2024 | 60 | 0.210 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2020 | 24 | 0.210 |
Why?
|
| Homozygote | 3 | 2020 | 201 | 0.210 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 149 | 0.210 |
Why?
|
| Benzimidazoles | 2 | 2016 | 109 | 0.210 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2024 | 141 | 0.210 |
Why?
|
| Aged | 10 | 2024 | 19943 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 498 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 429 | 0.210 |
Why?
|
| Thrombospondin 1 | 2 | 2013 | 21 | 0.200 |
Why?
|
| Thyroid Gland | 1 | 2024 | 280 | 0.200 |
Why?
|
| Candidiasis | 1 | 2022 | 37 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2017 | 1720 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 177 | 0.190 |
Why?
|
| Middle Aged | 11 | 2024 | 27030 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1398 | 0.190 |
Why?
|
| Proton Therapy | 1 | 2021 | 36 | 0.180 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 62 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 43 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 333 | 0.180 |
Why?
|
| Child | 15 | 2020 | 7334 | 0.180 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 531 | 0.180 |
Why?
|
| Child, Preschool | 10 | 2020 | 3818 | 0.180 |
Why?
|
| Terminator Regions, Genetic | 1 | 2020 | 14 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2012 | 228 | 0.170 |
Why?
|
| Eukaryotic Cells | 1 | 2020 | 44 | 0.170 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2020 | 1 | 0.170 |
Why?
|
| Adaptor Protein Complex 4 | 1 | 2020 | 2 | 0.170 |
Why?
|
| Meiosis | 1 | 2020 | 83 | 0.170 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2020 | 9 | 0.170 |
Why?
|
| Adult | 15 | 2024 | 27532 | 0.170 |
Why?
|
| Oncogene Proteins | 2 | 2010 | 64 | 0.170 |
Why?
|
| Mitosis | 2 | 2010 | 154 | 0.160 |
Why?
|
| Peptide Hydrolases | 1 | 2020 | 99 | 0.160 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 1163 | 0.160 |
Why?
|
| Collagen Type XII | 1 | 2019 | 1 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2019 | 704 | 0.160 |
Why?
|
| Protein Isoforms | 2 | 2018 | 283 | 0.160 |
Why?
|
| Intraoperative Care | 1 | 2020 | 85 | 0.160 |
Why?
|
| Cervical Vertebrae | 2 | 2019 | 180 | 0.160 |
Why?
|
| Mastectomy, Segmental | 1 | 2020 | 101 | 0.150 |
Why?
|
| Ephrin-A5 | 1 | 2018 | 1 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 4 | 1 | 2018 | 1 | 0.150 |
Why?
|
| Chromosome Breakpoints | 1 | 2018 | 15 | 0.150 |
Why?
|
| Phenotype | 4 | 2018 | 2498 | 0.150 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 20 | 0.150 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 237 | 0.150 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Dendritic Spines | 1 | 2018 | 15 | 0.150 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group F-H | 1 | 2018 | 2 | 0.150 |
Why?
|
| K562 Cells | 1 | 2018 | 47 | 0.150 |
Why?
|
| Protein Phosphatase 2 | 1 | 2018 | 17 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2019 | 66 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 61 | 0.150 |
Why?
|
| Infant | 7 | 2020 | 3218 | 0.150 |
Why?
|
| Intercellular Junctions | 1 | 2018 | 68 | 0.150 |
Why?
|
| Chromosome Disorders | 1 | 2018 | 112 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 188 | 0.150 |
Why?
|
| Craniofacial Dysostosis | 1 | 2018 | 12 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 132 | 0.150 |
Why?
|
| Micrognathism | 1 | 2018 | 11 | 0.150 |
Why?
|
| Homologous Recombination | 1 | 2018 | 53 | 0.150 |
Why?
|
| Neuroglia | 1 | 2018 | 102 | 0.150 |
Why?
|
| Hand Deformities, Congenital | 1 | 2018 | 15 | 0.150 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 60 | 0.150 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2017 | 4 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6916 | 0.150 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2017 | 2 | 0.150 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2017 | 6 | 0.140 |
Why?
|
| Craniofacial Abnormalities | 1 | 2018 | 35 | 0.140 |
Why?
|
| Isoleucine-tRNA Ligase | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 167 | 0.140 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 32 | 0.140 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 593 | 0.140 |
Why?
|
| Molecular Weight | 6 | 2016 | 332 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 262 | 0.140 |
Why?
|
| Mice, Knockout | 4 | 2017 | 2087 | 0.140 |
Why?
|
| Levodopa | 1 | 2017 | 38 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3775 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 159 | 0.140 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2017 | 20 | 0.140 |
Why?
|
| Congenital Hypothyroidism | 1 | 2018 | 80 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 343 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 332 | 0.130 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 336 | 0.130 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2017 | 102 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 1181 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2017 | 132 | 0.130 |
Why?
|
| Proteomics | 1 | 2018 | 246 | 0.130 |
Why?
|
| Adolescent | 12 | 2020 | 9504 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2019 | 708 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2024 | 1684 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2017 | 157 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2018 | 3508 | 0.130 |
Why?
|
| Prognosis | 6 | 2024 | 3872 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 530 | 0.120 |
Why?
|
| Genome, Human | 2 | 2019 | 799 | 0.120 |
Why?
|
| Taxoids | 1 | 2016 | 126 | 0.120 |
Why?
|
| Computational Biology | 1 | 2019 | 566 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2017 | 246 | 0.120 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 30 | 0.120 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 55 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2015 | 23 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 200 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 355 | 0.120 |
Why?
|
| Sulfasalazine | 1 | 1995 | 34 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 310 | 0.120 |
Why?
|
| Genomics | 1 | 2020 | 806 | 0.120 |
Why?
|
| Aortic Rupture | 1 | 2015 | 58 | 0.120 |
Why?
|
| Blotting, Western | 5 | 2016 | 795 | 0.110 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2004 | 33 | 0.110 |
Why?
|
| RNA, Small Interfering | 4 | 2020 | 561 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2017 | 1076 | 0.110 |
Why?
|
| Mice | 8 | 2018 | 12110 | 0.110 |
Why?
|
| Chromosomal Instability | 2 | 2010 | 20 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2013 | 731 | 0.110 |
Why?
|
| Centrosome | 2 | 2010 | 22 | 0.110 |
Why?
|
| Angiopoietin-2 | 1 | 2013 | 21 | 0.110 |
Why?
|
| Histone Acetyltransferases | 1 | 2013 | 44 | 0.110 |
Why?
|
| Animals | 9 | 2018 | 28003 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2018 | 323 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 3360 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 101 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1477 | 0.100 |
Why?
|
| Proteins | 1 | 2018 | 803 | 0.100 |
Why?
|
| Pedigree | 3 | 2020 | 966 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1995 | 351 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 167 | 0.090 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2011 | 16 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2016 | 425 | 0.090 |
Why?
|
| Smad Proteins | 1 | 2011 | 44 | 0.090 |
Why?
|
| Myofibroblasts | 1 | 2011 | 50 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 214 | 0.090 |
Why?
|
| cdc25 Phosphatases | 1 | 2010 | 19 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2448 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2021 | 9703 | 0.090 |
Why?
|
| S Phase | 1 | 2010 | 63 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2447 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 30 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2004 | 909 | 0.080 |
Why?
|
| Neurons | 1 | 2018 | 1596 | 0.080 |
Why?
|
| Cytoplasm | 3 | 2016 | 284 | 0.080 |
Why?
|
| Purines | 1 | 2010 | 97 | 0.080 |
Why?
|
| Poland | 2 | 2019 | 18 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2016 | 2978 | 0.080 |
Why?
|
| Cell Division | 1 | 2010 | 701 | 0.080 |
Why?
|
| G1 Phase | 3 | 2017 | 67 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 260 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2011 | 767 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 2556 | 0.070 |
Why?
|
| Syndrome | 2 | 2018 | 449 | 0.070 |
Why?
|
| Cystatins | 1 | 2006 | 5 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 760 | 0.060 |
Why?
|
| Urogenital Abnormalities | 1 | 2006 | 20 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 5430 | 0.060 |
Why?
|
| Biomarkers | 2 | 2018 | 1850 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2009 | 0.060 |
Why?
|
| Hypertension | 1 | 2011 | 763 | 0.060 |
Why?
|
| Carcinoma, Lobular | 2 | 2020 | 81 | 0.060 |
Why?
|
| Alleles | 2 | 2018 | 1141 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2368 | 0.060 |
Why?
|
| Leptin | 1 | 2005 | 104 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1592 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2020 | 1142 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2018 | 2037 | 0.060 |
Why?
|
| Platelet Count | 1 | 2004 | 92 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2020 | 160 | 0.060 |
Why?
|
| Body Height | 1 | 2004 | 102 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2016 | 612 | 0.050 |
Why?
|
| Prednisone | 1 | 2004 | 254 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2794 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2022 | 2 | 0.050 |
Why?
|
| Blindness, Cortical | 1 | 2002 | 8 | 0.050 |
Why?
|
| Candida albicans | 1 | 2022 | 31 | 0.050 |
Why?
|
| Linear Energy Transfer | 1 | 2021 | 5 | 0.050 |
Why?
|
| Relative Biological Effectiveness | 1 | 2021 | 14 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 133 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 140 | 0.050 |
Why?
|
| Radiometry | 1 | 2021 | 57 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2022 | 148 | 0.050 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2001 | 12 | 0.050 |
Why?
|
| Azure Stains | 1 | 2021 | 6 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 188 | 0.050 |
Why?
|
| Methylene Blue | 1 | 2021 | 18 | 0.050 |
Why?
|
| Xanthenes | 1 | 2021 | 23 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2001 | 66 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 38 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2001 | 55 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1145 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 520 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 59 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2001 | 77 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 795 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 299 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 111 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2394 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 433 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 250 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 989 | 0.040 |
Why?
|
| Saccharomycetales | 1 | 2019 | 11 | 0.040 |
Why?
|
| Seizures | 1 | 2002 | 312 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 390 | 0.040 |
Why?
|
| Genome, Fungal | 1 | 2019 | 35 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 612 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 2035 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 514 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2012 | 828 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 90 | 0.040 |
Why?
|
| Facies | 1 | 2018 | 27 | 0.040 |
Why?
|
| Karyotype | 1 | 2018 | 34 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 260 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 666 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2018 | 276 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 569 | 0.040 |
Why?
|
| Joint Instability | 1 | 2019 | 91 | 0.040 |
Why?
|
| Genes, Recessive | 1 | 2017 | 87 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 800 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 680 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2017 | 28 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 968 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 430 | 0.030 |
Why?
|
| Protein Domains | 1 | 2017 | 142 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 163 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 6624 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 383 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2017 | 168 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1763 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 128 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 376 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 456 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 1550 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 403 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2017 | 2517 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2017 | 442 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 1008 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2013 | 6 | 0.030 |
Why?
|
| Pyrans | 1 | 2013 | 10 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2013 | 47 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 38 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 52 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2020 | 1392 | 0.030 |
Why?
|
| Hyperlipoproteinemia Type V | 1 | 1992 | 1 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 112 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 1503 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 312 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 1995 | 179 | 0.030 |
Why?
|
| Reference Values | 2 | 2004 | 660 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 810 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 1863 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 296 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2505 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1589 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 288 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 734 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 64 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 1052 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 891 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 87 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 807 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 328 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 133 | 0.020 |
Why?
|
| Purpura | 1 | 1990 | 13 | 0.020 |
Why?
|
| Cyclin B | 1 | 2010 | 18 | 0.020 |
Why?
|
| Diabetes Insipidus | 1 | 1990 | 17 | 0.020 |
Why?
|
| Ploidies | 1 | 2010 | 41 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 502 | 0.020 |
Why?
|
| Ribs | 1 | 1990 | 47 | 0.020 |
Why?
|
| Sarcoma, Ewing | 1 | 1990 | 43 | 0.020 |
Why?
|
| Age Factors | 2 | 2006 | 1905 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2010 | 78 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 3509 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 495 | 0.020 |
Why?
|
| Models, Biological | 1 | 2017 | 1786 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 354 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 296 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 291 | 0.020 |
Why?
|
| Postmenopause | 1 | 2010 | 102 | 0.020 |
Why?
|
| Nitriles | 1 | 2010 | 158 | 0.020 |
Why?
|
| Triazoles | 1 | 2010 | 108 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2002 | 8740 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 523 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2902 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 515 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 403 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1990 | 313 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1743 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1513 | 0.020 |
Why?
|
| Cystatin C | 1 | 2006 | 28 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 1990 | 324 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 1927 | 0.020 |
Why?
|
| Apolipoproteins A | 1 | 2005 | 10 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2005 | 36 | 0.010 |
Why?
|
| Creatinine | 1 | 2006 | 296 | 0.010 |
Why?
|
| Organ Size | 1 | 2006 | 375 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 280 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1310 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 171 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 977 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1399 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2005 | 237 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 322 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2001 | 18 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 100 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2001 | 87 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 754 | 0.010 |
Why?
|
| Urinary Tract | 1 | 1993 | 35 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1993 | 149 | 0.010 |
Why?
|
| Pituitary Gland, Posterior | 1 | 1990 | 3 | 0.010 |
Why?
|
| Atrophy | 1 | 1990 | 127 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 158 | 0.000 |
Why?
|
| Pneumonia | 1 | 1990 | 189 | 0.000 |
Why?
|